Allergan Announces Official Launch of the TrueTear Intranasal Neurostimulation Device

Source: Allergan

Allergan announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients.

TrueTear, a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to induce the production of natural tears, is a novel and innovative approach for those patients with inadequate tear production. In two clinical trials, TrueTear was shown to be safe and effective for temporarily increasing tear production in adult patients.

The neurostimulation device will be officially launched during the 2018 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators annual meetings being held April 13-17 in Washington, DC.

“TrueTear is the latest in a long line of innovations that have helped make Allergan a leading global eye care company. We are excited to add this drug-free, drop-free treatment option for adult patients with inadequate tear production to our current portfolio.  This milestone truly represents our company’s ongoing commitment to developing eye care products that help improve the lives of patients,”  Jag Dosanjh, Senior Vice President, US Eye Care, said in a company news release. “For more than 70 years, Allergan has remained focused on delivering the most innovative eye care products in the industry. TrueTear continues the proud heritage of our foundational philosophy: to bring innovative treatments to patients around the world.”

“As seen in clinical trials and in my own post-approval experience treating patients, TrueTear provides tiny pulses of energy within the nasal cavity to create tears and may be appropriate for most patients with inadequate tear production,” said John Sheppard, M.D., M.M. Sc., F.A.C.S., Professor of Ophthalmology, Eastern Virginia Medical School and President of Virginia Eye Consultants in Norfolk, Virginia. “TrueTear is the first device of its kind, providing a temporary increase in tear production with neurostimulation, thereby returning the ocular surface to a more normal physiologic state without prescribing drops or surgery.”


Related Content